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Introduction
TRAPS (TNF receptor associated periodic syndrome) is
a rare autoinflammatory disease that can touch children
and adults. It is caused by the mutation of TNFRSF1A
encoding for TNF receptor. The main complication is
amyloidosis.
Objectives
The aim is to increase knowledge about the disease
to make the diagnostic easier. Another purpose is to
analyse the biotherapy treatment in TRAPS.
Methods
It consists in a retrospective descriptive multicentre
study in French and Belgian hospitals. Data were
directly collected thanks to files of patients.
Inclusion criteria are: presence of TNFRAF1A muta-
tion, recurrent symptoms. Exclusion criteria: presence of
MEFV mutation.
Results
We have included 25 kids and 16 adults (isolated cases
and 9 families), coming from France (45%), south of
Europe (22%), north of Europe (10%), Maghreb (9%),
and east of Europe (6%). Two kids have homozygous
mutation for MEFV and one heterozygous. 19,5% of the
patients have had an appendectomy. 26 patients have
recurrent fever in their family, among which 22 have
TRAPS.
The disease starts mainly before the age of 5 years
(61,1%) but for 13,5%, it begins in adulthood. The aver-
age of the time of diagnosis (delay between first symp-
toms and diagnosis) is 12,9 years.
51% of R92Q heterozygous mutation, 10% of T50M,
7% de L67P, 5% C29S, 5% C43S have been encountered.
2% of the patients have R92Q homozygous, 2% Q82R
and R92Q heterozygous.
The seizures occur 9,7 times a year on average (<1 to
48 times a year), last 10,8 days on average (1 to 49
days). A trigger exists in 43.9% of the cases. 78% have
rheumatologic symptoms, 70,7% arthralgia (mainly
knees, spine, elbows), 22% arthritis (small and big
joints). 24,4% have chest pain, 7,3%serositis. Dermatolo-
gical symptoms (70,7%) are frequent (56,1% rash). Lots
of patients have abdominal pain (70,7%), myalgia
(65,7%), asthenia (48,8%). Headache is present in 39% of
this population. Only 3 patients have periorbital
oedema. Between the seizures there is no symptomatol-
ogy, but in 24% of the cases inflammatory syndrome
persists.
We note the interest to dose the Serum Amyloid A to
detect the activity of disease between the crises.
The screening of proteinuria was positive in 29% of
the cases but no amyloidis is reported.Correlation
between R92Q mutation and hematologic symptoms
(splenomegaly, adenopathy) was found between geno-
type and phenotype.
Corticosteroids were used for treatment of seizures.
Only 9 patients were treated by biotherapy. Etanercept
was efficient in a first time, but not always in the long
term. Anakinra always allowed remission.
Conclusion
77%of this population of patients with TNFRSF1A
mutation has 3 symptoms among arthralgia, rash,
abdominal pain, myalgia, asthenia and headache. Etaner-
cept is not always efficient and Anakinra is a good alter-
native for the treatment. The inscription of the patients
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in autoinflammatory disease registers would allow a bet-
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